Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Down – Should You Sell?

by · The Cerbat Gem

Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $48.16, but opened at $42.90. Swedish Orphan Biovitrum shares last traded at $42.90, with a volume of 150 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on BIOVF shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Swedish Orphan Biovitrum has a consensus rating of “Moderate Buy”.

View Our Latest Stock Analysis on BIOVF

Swedish Orphan Biovitrum Trading Down 10.9%

The firm has a fifty day moving average of $48.25 and a 200 day moving average of $46.18. The firm has a market capitalization of $15.27 billion, a PE ratio of 95.34 and a beta of 0.33. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88.

Swedish Orphan Biovitrum Company Profile

(Get Free Report)

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions.

Recommended Stories